Ramsay reports challenging Q3 FY2022 due to COVID-19 related bans

Ramsay Health Care Limited (ASX: RHC) has released trading update for Q3 FY2022. The Company highlighted that Q3 was a challenging period because of the significant level of disruption in the business as a result of rising COVID cases in the community. Now, it is seeing rise in the activity levels as surgical restrictions is lifted.

RHC would be investing in its platform future growth, including its brownfield expansion plans along with completing the Elysium transaction. The focus is on integrating recent acquisitions and driving synergies to improve returns.

It is also focused on its short- and long-term plans to address staff shortage as well as COVID-19 related among its frontline teams.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Suite 1A, Level 2, 802-808 Pacific Highway, Gordon NSW 2072, Australia | 1800 005 780 | info@kapitales.com.au